Medicover AB Series B
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. Its Healthcare Services include service outpatient and inpatient care; dental services; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness; hospital care; and preventive care services. The company's Diagnostic Servi… Read more
Medicover AB Series B (0RPS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.118x
Based on the latest financial reports, Medicover AB Series B (0RPS) has a cash flow conversion efficiency ratio of 0.118x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr57.30 Million) by net assets (Skr485.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medicover AB Series B - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Medicover AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medicover AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicover AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aptus Value Housing Finance India Limited
NSE:APTUS
|
-0.027x |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
-0.032x |
|
Guangdong Sky Dragon Printing Ink Group Co Ltd
SHE:300063
|
0.063x |
|
Craftsman Automation Limited
NSE:CRAFTSMAN
|
0.046x |
|
Northern Data AG
PINK:NDTAF
|
-0.021x |
|
Alliance Material Co., Ltd.
TWO:3595
|
0.027x |
|
Eastcompeace Technology Co Ltd
SHE:002017
|
0.079x |
|
Foran Mining Corporation
OTCQX:FMCXF
|
0.000x |
Annual Cash Flow Conversion Efficiency for Medicover AB Series B (2014–2024)
The table below shows the annual cash flow conversion efficiency of Medicover AB Series B from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr489.30 Million | Skr261.90 Million | 0.535x | +37.94% |
| 2023-12-31 | Skr528.30 Million | Skr205.00 Million | 0.388x | -89.58% |
| 2022-12-31 | Skr510.80 Million | Skr1.90 Billion | 3.723x | -6.21% |
| 2021-12-31 | Skr562.10 Million | Skr2.23 Billion | 3.969x | +1130.20% |
| 2020-12-31 | Skr483.50 Million | Skr156.00 Million | 0.323x | +32.94% |
| 2019-12-31 | Skr359.70 Million | Skr87.30 Million | 0.243x | +77.05% |
| 2018-12-31 | Skr323.90 Million | Skr44.40 Million | 0.137x | -17.15% |
| 2017-12-31 | Skr304.00 Million | Skr50.30 Million | 0.165x | -36.88% |
| 2016-12-31 | Skr98.80 Million | Skr25.90 Million | 0.262x | -14.87% |
| 2015-12-31 | Skr93.20 Million | Skr28.70 Million | 0.308x | +28.43% |
| 2014-12-31 | Skr90.50 Million | Skr21.70 Million | 0.240x | -- |